Research ExplorerPublicationsDual antibody induction and de novo use of everolimus enable...

Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation

Standard

Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation. / Li, Jun; Koch, Martina; Kramer, Kathrin; Kloth, Katja; El Rahman Abu Ganim, Abd; Scheidat, Silke; Rinninger, Franz; Thaiss, Friedrich; Gulati, Amit; Herden, Uta; Achilles, Eike; Fischer, Lutz; Nashan, Bjoern.

In: TRANSPL IMMUNOL, Vol. 50, 10.2018, p. 26-33.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Li, J, Koch, M, Kramer, K, Kloth, K, El Rahman Abu Ganim, A, Scheidat, S, Rinninger, F, Thaiss, F, Gulati, A, Herden, U, Achilles, E, Fischer, L & Nashan, B 2018, 'Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation', TRANSPL IMMUNOL, vol. 50, pp. 26-33. https://doi.org/10.1016/j.trim.2018.06.001

APA

Li, J., Koch, M., Kramer, K., Kloth, K., El Rahman Abu Ganim, A., Scheidat, S., Rinninger, F., Thaiss, F., Gulati, A., Herden, U., Achilles, E., Fischer, L., & Nashan, B. (2018). Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation. TRANSPL IMMUNOL, 50, 26-33. https://doi.org/10.1016/j.trim.2018.06.001

Vancouver

Li J, Koch M, Kramer K, Kloth K, El Rahman Abu Ganim A, Scheidat S et al. Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation. TRANSPL IMMUNOL. 2018 Oct;50:26-33. https://doi.org/10.1016/j.trim.2018.06.001

Bibtex

@article{f4644333b9964ac48c226203669bf37d,
title = "Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation",
abstract = "BACKGROUND: To be an optimal immunosuppressive regimen after simultaneous pancreas kidney transplantation (SPK), low dose calcineurin inhibitor and early withdrawal of corticosteroids are desired.METHODS: Immunosuppressive regimen as such has been conducted consecutively in SPK recipients since 2009 in authors' institute. In addition to tacrolimus in low trough level and early corticosteroid withdraw, dual induction with basiliximab and low-dose thymoglobulin in combination with everolimus are the important components of the protocol.RESULTS: 25 consecutive primary SPK recipients were included in the study. Lymphocyte depletion by low dose thymoglobulin was limited to two weeks, and CD25 coating with basiliximab was detectable for 4 weeks. The BPAR within the first 12 months was 13%. During a median follow-up of 58 months, new-onset diabetes mellitus and renal function deterioration were rare events. No cytomegalovirus activation was encountered. The patients, pancreas and kidney graft survival at 1-year and 5-year was 100% and 94.4%, 95.8% and 95.8%, 100% and 100% respectively.",
keywords = "Journal Article",
author = "Jun Li and Martina Koch and Kathrin Kramer and Katja Kloth and {El Rahman Abu Ganim}, Abd and Silke Scheidat and Franz Rinninger and Friedrich Thaiss and Amit Gulati and Uta Herden and Eike Achilles and Lutz Fischer and Bjoern Nashan",
note = "Copyright {\textcopyright} 2017. Published by Elsevier B.V.",
year = "2018",
month = oct,
doi = "10.1016/j.trim.2018.06.001",
language = "English",
volume = "50",
pages = "26--33",
journal = "TRANSPL IMMUNOL",
issn = "0966-3274",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation

AU - Li, Jun

AU - Koch, Martina

AU - Kramer, Kathrin

AU - Kloth, Katja

AU - El Rahman Abu Ganim, Abd

AU - Scheidat, Silke

AU - Rinninger, Franz

AU - Thaiss, Friedrich

AU - Gulati, Amit

AU - Herden, Uta

AU - Achilles, Eike

AU - Fischer, Lutz

AU - Nashan, Bjoern

N1 - Copyright © 2017. Published by Elsevier B.V.

PY - 2018/10

Y1 - 2018/10

N2 - BACKGROUND: To be an optimal immunosuppressive regimen after simultaneous pancreas kidney transplantation (SPK), low dose calcineurin inhibitor and early withdrawal of corticosteroids are desired.METHODS: Immunosuppressive regimen as such has been conducted consecutively in SPK recipients since 2009 in authors' institute. In addition to tacrolimus in low trough level and early corticosteroid withdraw, dual induction with basiliximab and low-dose thymoglobulin in combination with everolimus are the important components of the protocol.RESULTS: 25 consecutive primary SPK recipients were included in the study. Lymphocyte depletion by low dose thymoglobulin was limited to two weeks, and CD25 coating with basiliximab was detectable for 4 weeks. The BPAR within the first 12 months was 13%. During a median follow-up of 58 months, new-onset diabetes mellitus and renal function deterioration were rare events. No cytomegalovirus activation was encountered. The patients, pancreas and kidney graft survival at 1-year and 5-year was 100% and 94.4%, 95.8% and 95.8%, 100% and 100% respectively.

AB - BACKGROUND: To be an optimal immunosuppressive regimen after simultaneous pancreas kidney transplantation (SPK), low dose calcineurin inhibitor and early withdrawal of corticosteroids are desired.METHODS: Immunosuppressive regimen as such has been conducted consecutively in SPK recipients since 2009 in authors' institute. In addition to tacrolimus in low trough level and early corticosteroid withdraw, dual induction with basiliximab and low-dose thymoglobulin in combination with everolimus are the important components of the protocol.RESULTS: 25 consecutive primary SPK recipients were included in the study. Lymphocyte depletion by low dose thymoglobulin was limited to two weeks, and CD25 coating with basiliximab was detectable for 4 weeks. The BPAR within the first 12 months was 13%. During a median follow-up of 58 months, new-onset diabetes mellitus and renal function deterioration were rare events. No cytomegalovirus activation was encountered. The patients, pancreas and kidney graft survival at 1-year and 5-year was 100% and 94.4%, 95.8% and 95.8%, 100% and 100% respectively.

KW - Journal Article

U2 - 10.1016/j.trim.2018.06.001

DO - 10.1016/j.trim.2018.06.001

M3 - SCORING: Journal article

C2 - 29885442

VL - 50

SP - 26

EP - 33

JO - TRANSPL IMMUNOL

JF - TRANSPL IMMUNOL

SN - 0966-3274

ER -